NCT07780968Not yet recruiting
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA) (HER2+ la/m GEA).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 19 Aug 2026
- Start date
- 30 Nov 2026
- Primary completion date
- 1 Oct 2031
- Lead sponsor
- Jazz Pharmaceuticals
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07780968
What you commit to
- Study type: Observational
- Planned participants: 300
- From 30 Nov 2026 to the primary completion date, 1 Oct 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving a zanidatamab-containing therapy as part of a clinical trial or expanded access program
- Received zanidatamab prior to the approval date by the FDA for HER2+ la/m GEA
- Received the first infusion of zanidatamab prior to providing study consent
- For patients initiating chemotherapy backbone first, more than 2 months have elapsed before the first dose of zanidatamab
Who the study is looking for
- Histologically confirmed HER2-positive (defined as IHC3+ or IHC2+ with ISH positivity) locally advanced or metastatic GEA
- Documented plan to initiate a zanidatamab-containing therapy as 1L treatment
- Sufficient cognitive capacity and language proficiency to complete patient-reported outcomes (PRO) questions
- 18 years of age or older on the date of initiating 1L zanidatamab-containing therapy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas - MD Anderson Cancer Center Gastrointestinal Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| UCI Health - Chao Family Comprehensive Cancer Center Coordinator of this site? Confirm its status | Orange | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.